8-K filed August 6, 2026, 8:20 AM ET ticker ENSC CIK 0001716947

M&A confidence high sentiment neutral materiality 0.85

Ensysce acquires Cy Biopharma, issues Series C Preferred, raises ~$43M in PIPE

Ensysce Biosciences, Inc.

Acquired Cy Biopharma on Aug 5, 2026; Cy stockholders received 282,122 shares of Series C Preferred Stock (convertible 1:1,000 into common).
Raised ~$43M via PIPE: 120,260 Series C shares in two tranches; initial close Aug 7, 2026, milestone tranche subject to clinical trial.
Lynn Kirkpatrick resigned as President; James Morrison (founder of Cy) appointed President and director, to become CEO after stockholder vote.
Eliminated Series B Preferred Stock; all outstanding shares converted into 3,229,276 common shares; Certificate of Elimination filed.
Certain Cy stockholders and company insiders subject to 180-day lock-up on shares received in the merger.

item 1.01 item 5.03 item 2.01 item 3.02 item 3.03 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Morrison

Director

ENSC · Ensysce Biosciences, Inc.

Effective: 2026-08-05
Filed: August 6, 2026, 8:20 AM ET

the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing

Appointed

James Morrison

Chief Executive Officer

ENSC · Ensysce Biosciences, Inc.

Filed: August 6, 2026, 8:20 AM ET

appointed Mr. Morrison as Chief Executive Officer effective upon approval of the Meeting Proposals.

Appointed

James Morrison

President

ENSC · Ensysce Biosciences, Inc.

Effective: 2026-08-05
Filed: August 6, 2026, 8:20 AM ET

the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing

Role change

Lynn Kirkpatrick

President

ENSC · Ensysce Biosciences, Inc.

Effective: 2026-08-05
Successor: James Morrison
Filed: August 6, 2026, 8:20 AM ET

on August 5, 2026, Lynn Kirkpatrick resigned from her position as President of the Company, effective immediately upon the Closing.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Morrison was appointed as Director at Ensysce Biosciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Morrison was appointed as Chief Executive Officer at Ensysce Biosciences, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

appointed Mr. Morrison as Chief Executive Officer effective upon approval of the Meeting Proposals.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Morrison was appointed as President at Ensysce Biosciences, Inc..

Action: appointed
Role: President

Exact text from the filing

the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lynn Kirkpatrick resigned as President at Ensysce Biosciences, Inc..

Action: resigned
Role: President

Exact text from the filing

on August 5, 2026, Lynn Kirkpatrick resigned from her position as President of the Company, effective immediately upon the Closing.

View on SEC.gov

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-036268

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.